Articles on Access Issues


     •     Promoting Access to Medical Technologies and Innovation. WHO, WIP, WTO. February 2013

     •     SLOW IDEAS: Some innovations spread fast. How do you speed the ones that don’t? A Gawande. The New Yorker.  July 29, 2013.

     •     Sustainable health and multi-stakeholder action: Lessons learned from the MDGs. IFPMA. September 2013.

     •     From Promises to Progress: The First Annual Report on the London Declaration on NTDs. Uniting to combat NTDs.  January 2013.

     •     Implementing new health interventions in developing countries: Why do we lose a decade or more? Brooks A et al. BMC Public Health. 12:683. 21 August 2012

     •     Improving Access to Essential Medicines Through Public-Private Partnerships. IVAC. June 2011

     •     Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Wells WW and Brooks A. Health Research Policy and Systems 2011, 9:15

     •     Ensuring Access to Products Developed by PDPs.  AD Brooks et al.  Innovation Strategy Today.  Volume 3 (1).  January 2010

     •     Innovation in Action: Policies to accelerate the development and delivery of global health tools. Global Health Technologies Coalition (GHTC).  April 2010.

     •     Trading Away Access to Medicines: How the European Union’s trade agenda has taken a wrong turn. Health Action International (HAI) and Oxfam International.  October 2009

     •     Equitable access: Research challenges for health in developing countries. A Report on Forum 11. Global Forum for Health Research.  2008.

     •     Registering new drugs for low-income countries: the African challenge. Moran M et al. PLoS Medicine. 1 February 2011; 8(2):e1000411.

     •     Regulatory watch: FDA guidance on co-developing investigational drugs. Nature Reviews Drug Discovery. 1 February 2011; 10:86.

PDP Access Steering Committee

     •     Economic Appraisals for Product Development Partnership. Report from the PDP Access group meeting in January 2013.  April 2013.

     •     Access metrics: Tracking Progress and Success for PDPs. PDP Access Steering Committee Working Paper. December 2011.

     •     Summary analysis of Access Costs. PDP Access Steering Committee Working Paper. December 2011.

     •     PDP Access Steering Committee:  Second access meeting  Facilitating equitable access to new health products in low income countries held 27-28 July 2010.   Meeting Report, Discussion Papers and Presentations.

PDP/s Access Related Reports


     •     Planning for Adult Vaccination in Middle- and Low-Income Countries, HIV, TB, and Malaria Workshop. September 2013.

Dengue Vaccine Initiative

     •     Planning for the Introduction of Dengue Vaccines: Meeting Report of the Americas Dengue Prevention Board - Highlights.  Dengue Vaccine Initiative.  15 February 2012.

     •     Consolidated Points for Consideration for First Introductions of Dengue Vaccines.  Dengue Vaccine Initiative

     •     Points for Consideration for First Introductions of Dengue Vaccines. Report of the Asia-Pacific Dengue Prevention Board 2012. August 2012.

     •     PDVI: Dengue Vaccine Adoption in Developing Countries:  Some costs & financing issues. PDVI_Occasional_Paper_1.pdf July 2010

     •     PDVI: Dengue Vaccines: Introduction and Delivery Issues.  PDVI_Occasional_Paper_2.pdf September 2010

     •     PDVI Occasional Paper 3. Challenges concerning Diagnosis, Surveillance, Burden of Disease, and Economics of Dengue. September 2010.


     •     Access in Action:  A review of MMVs Access Activities.  June 2011.

     •     MMV In Access:  Facilitating delivery of effective anti-malarials (April 2008)

     •     Ensuring Success:  MMV Access Strategy- Presentation (September 2007)


     •     Procurement and Pricing of New Vaccines for Developing Countries.  August 2008. IAVI Policy Brief

     •     The Introduction of New Health Technologies in India (Policy Research Working Paper).  April 2007.

     •     Forecasting Demand for Preventative HIV Vaccines in India.  International AIDS Vaccine Initiative. June 2007

     •     The Impact of an AIDS Vaccine in Developing Countries: A New Model and Preliminary Results. October 2006.  IAVI Policy Research Working Paper 8


     •     Preparing for Access to Microbicides and the Dapivirine Ring for HIV Prevention: Preliminary Strategy.  2011.

     •     Identifying Optimal Strategies for Microbicide Distribution in India and South Africa: Modelling and cost-effectiveness analyses 2008

     •     Microbicides Access Forum 2008 Final Report. 2008

     •     Planning for microbicide access in developing countries:  Lessons from the introduction of contraceptive technologies (July 2007)

     •     Financing Mechanisms for Microbicide R&D and Future Introduction. 2007

     •     IPM Worldwide Manufacturing Capabilities Survey (2007)  

TB Alliance

     •     Implications of the current tuberculosis treatment landscape for future regimen change. Wells WA et al. The International Journal of Tuberculosis and Lung Disease, Volume 15, Number 6, June 2011 , pp. 746-753(8)

     •     New TB Regimens: What Countries Want (September 2009)

     •     Pathway to Patients (May 2007)


     •     PATH's Framework for Product Introduction (2007)


     •     Access related webpages:  Preparing for Vaccines

     •     Analysis of WHO Policy Development Processes for a New Intervention: Malaria Vaccines. May 2008

     •     Malaria Vaccine Decision Making Framework.  Process launched by MVI and WHO launched in 2006 with support from USAID and the Bill & Melinda Gates Foundation

     •     Market Assessment for Malaria Vaccines.  Presentation.  February 2005

Other articles/ reports on Access Issues

HPV Vaccines

     •     HPV Vaccine Adoption in Developing Countries: Cost and Financing Issues.  A joint IAVI and PATH publication.  December 2007

     •     Introducing HPV Vaccines in Developing Countries: Overcoming the Challenges.  September 2005


     •     Scaling up interventions to achieve global tuberculosis control: progress and new developments. Raviglione M et al. The Lancet, Volume 379, Issue 9829, Pages 1902 - 1913, 19 May 2012


     •     Expanding Access to long-lasting insecticide-treated nets (LLINs): A Global Market Dynamics Approach. Results for Development Institute. April 2012.

     •     Closing the access barrier for effective antimalarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. Talisuna AO et al. Malaria Journal 2012, 11:356 doi:10.1186/1475-2875-11-356. Published October 29

     •     Feasibility of distributing rapid diagnostic tests for Malaria in the retail sector: Evidence from an implementation study in Uganda. Cohen J et al. PLoS ONE 7(11): e48296. doi:10.1371/journal.pone.0048296

     •     Early experiences on the feasibility, acceptability, and use of malaria rapid diagnostic tests at peripheral health centres in Uganda-insights into some barriers and facilitators. Implementation Science 2012, 7:5. Published online 23 January 2012

     •     Universal access to malaria medicines: innovation in financing and delivery. Adeyi O & Atun R. The Lancet, Volume 376, Issue 9755, Pages 1869 - 1871, 27 November 2010

     •     APPMG Fourth Report: Delivering Malaria Control to Those in Need. All-Party Parliamentary Group on Malaria and Neglected Tropical Diseases.  December 2008.

     •     Equity and adequacy of international donor assistance for global malaria control: an analysis of populations at risk and external funding commitments. Snow RW et al. Volume 376, Issue 9750, Pages 1409 - 1416, 23 October 2010

Hep B

     •     Introduction of Hepatitis B Vaccine:  Reflections on Innovation.  R Mahoney.  Innovation Strategy Today.  Volume 3 (1).  January 2010


     •     Scale-up of diagnostics for multidrug resistant tuberculosis. Caws M et al. The Lancet Infectious Diseases, Volume 10, Issue 10, Pages 656 - 658, October 2010

     •     Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. Pai NP et al. PLoS Med 9(9): e1001306. doi:10.1371/journal.pmed.1001306

Demand Forecasting

     •     A Risky Business: Saving Money and Improving Global Health Through Better Demand Forecasts.  Center for Global Development Report (May 2007)


     •     Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Crawford KW et al. The Lancet Infectious Diseases, Volume 12, Issue 7, Pages 550 - 560, July 2012

     •     Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. Mahoney RT et al. Vaccine. Volume 30, Issue 32, 6 July 2012, Pages 4892–4896